TransCode Therapeutics reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics. Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment. TransCode and Akribion are collaborating to develop a technology that combines Akribion’s cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode’s TTX nucleic acid delivery platform. G-dase E has shown encouraging in vitro results in cells but requires an effective delivery vehicle, such as TTX, to reach intended targets in the body. Proof-of-concept studies to date suggest that Akribion’s G-dase E ribonucleoprotein complexes could be conjugated to TransCode’s TTX delivery platform, suggesting that the drug candidate could be formulated as intended. These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RNAZ:
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
- Transcode Therapeutics reports publication of U.S. patent application
- TransCode Therapeutics Regains Nasdaq Compliance Status
- Transcode regains compliance with Nasdaq stockholders’ equity requirement
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market